ARTICLE | Clinical News

Brilinta ticagrelor: Additional Phase III data

September 6, 2010 7:00 AM UTC

Researchers from Uppsala University and colleagues reported data from a subgroup analysis of 10,285 patients who provided DNA samples for genetic analysis in the double-blind, double-dummy, international Phase III PLATO trial showing that Brilinta outperformed Plavix clopidogrel even in patients expected to respond well to Plavix because they lacked polymorphisms associated with poor response to Plavix. Specifically, Brilinta performed better than Plavix in reducing the composite primary endpoint of time to first occurrence of any event from the composite of CV death, MI and stroke, irrespective of cytochrome P450 2C19 (CYP2C19) or P glycoprotein ( MDR1; ABCB1; P-gp; CD243) polymorphisms. Polymorphisms in the CYP2C19 and ABCB1 genes are thought to negatively affect Plavix responses. ...